F-1 F-1/A EX-FILING FEES 333-292790 0002020932 Agomab Therapeutics NV N/A N/A 0002020932 2026-01-28 2026-01-28 0002020932 1 2026-01-28 2026-01-28 0002020932 2 2026-01-28 2026-01-28 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

F-1

Agomab Therapeutics NV

Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial Effective Date

Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward

Newly Registered Securities
Fees to be Paid 1 Equity Common Shares, no nominal value per share, as represented by American Depositary Shares 457(a) 14,375,000 $ 17.00 $ 144,375,000.00 0.0001381 $ 19,938.19
Fees Previously Paid 2 Equity Common Shares, no nominal value per share, as represented by American Depositary Shares 457(o) $ 100,000,000.00 $ 13,810.00
Carry Forward Securities
Carry Forward Securities

Total Offering Amounts:

$ 244,375,000.00

$ 33,748.19

Total Fees Previously Paid:

$ 13,810.00

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 19,938.19

Offering Note

1

Note.1a. American Depositary Shares ("ADSs") issuable upon deposit of the common shares registered hereby are being registered pursuant to a separate Registration Statement on Form F-6. Each ADS represents one (1) common share. Note.1b. Includes 1,875,000 ADSs that the underwriters have the option to purchase. Note.1c. Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended (the "Securities Act").

2

See Offering Note.1a. Note. 2a. The Registrant previously paid a registration fee of $13,810.00 in accordance with Rule 457(o) under the Securities Act, in connection with initial filing of the Registration Statement on Form F-1 on January 16, 2026. Note. 2b. This Maximum Aggregate Offering Price was originally registered in accordance with Rule 457(o) and is now converted to Rule 457(a), contrary to being displayed as Rule 457(o) above.
Table 2: Fee Offset Claims and Sources ☑Not Applicable
Registrant or Filer Name Form or Filing Type File Number Initial Filing Date Filing Date Fee Offset Claimed Security Type Associated with Fee Offset Claimed Security Title Associated with Fee Offset Claimed Unsold Securities Associated with Fee Offset Claimed Unsold Aggregate Offering Amount Associated with Fee Offset Claimed Fee Paid with Fee Offset Source
Rules 457(b) and 0-11(a)(2)
Fee Offset Claims N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Fee Offset Sources N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Rule 457(p)
Fee Offset Claims N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Fee Offset Sources N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Table 3: Combined Prospectuses ☑Not Applicable

Security Type

Security Class Title

Amount of Securities Previously Registered

Maximum Aggregate Offering Price of Securities Previously Registered

Form Type

File Number

Initial Effective Date

N/A N/A N/A N/A N/A N/A N/A N/A